Benefits
Same-day performance on the hardest cognitive tasks (secondary finding)
A single 300 mg dose did not beat placebo on the trial's primary outcome, overall calmness. As a secondary result, the Zensera group did better than placebo on the hardest task switching trials five hours after the dose, and the hardest attention network trials trended the same way (p = 0.053). Word recall, rapid visual processing and paced addition scores did not differ. This is one Givaudan-funded trial, so the finding is preliminary.
Calmness: the outcome the trial was built around, and missed
Overall subjective calmness was the pre-specified primary aim of the trial, and it did not change versus placebo. The only calmness signal was a recovery pattern: calmness tended to be higher in the Zensera group before each later test session, but this was a statistical trend (p = 0.056) and follow-up comparisons were not significant. Zensera should not be presented as proven for stress or anxiety.
Long-term use has not been tested
Every published finding on Zensera comes from one acute test day after a single 300 mg dose, with measurements stopping at 5 hours. No study has examined daily or repeated use, and the trial authors wrote that research into chronic stress is still warranted. Any claim that benefits build with regular use is untested.
Mechanism of action
Stress-cognitive pathway botanical modulation
Animal and cell studies suggest lemon balm and its components, such as rosmarinic acid, may act on GABAergic, cholinergic and serotonergic signalling. Givaudan says Zensera™ was developed by high-throughput screening and optimized to activate GABA receptors and inhibit GABA transaminase, citing its own unpublished data. The human trial collected no blood samples, so it could not confirm absorption or test this mechanism.
Clinical trials
Randomized, double-blind, placebo-controlled parallel-group study of a single 300 mg dose (Mathews et al., Ther Adv Psychopharmacol 2026; PMID 41782777). The primary outcome, overall calmness, was not significant. A secondary cognitive result appeared at 5 hours.
106 healthy adults aged 18 to 40 with moderate subjective stress completed the study (130 enrolled). Randomized, double-blind, placebo-controlled, parallel-group design. 300 mg Zensera™ (Givaudan patent-pending lemon balm extract from Melissa officinalis L.) vs matching placebo. Cognitive function, mood, heart rate and BP measured at baseline, 1, 3, and 5 hours post-treatment during cognitive overload tasks. NCT06183372 (LemCog trial, University of Reading).
Primary outcome (overall calmness): not significant. Secondary: at 5 hours Zensera beat placebo on the hardest task switching trials (p = 0.026) and trended better on the hardest attention network trials (p = 0.053); word recall, rapid visual processing and paced addition did not differ. A calmness recovery pattern was only a trend (p = 0.056). No adverse events were reported. Givaudan-funded, with two Givaudan-employed co-authors; not independently replicated.